Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS -1.49% FCF Yield % is -71.17 as of Jul. 21, 2026. The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Genetic Signatures ranks worse than 93.43% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Genetic Signatures's FCF Yield % or its related term are showing as below:
ASX:GSS'
s FCF Yield % Range Over the Past 10 Years
Min: -100.32 Med: -8.01 Max: 9.21
Current: -71.17
During the past 11 years, the highest FCF Yield % of Genetic Signatures was 9.21%. The lowest was -100.32%. And the median was -8.01%.
ASX:GSS's FCF Yield % is ranked worse than 93.43% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.21
vs ASX:GSS: -71.17
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Genetic Signatures FCF Yield % Related Terms
Genetic Signatures FCF Yield % Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Genetic Signatures's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a FCF Yield % of -71.17 as of Jul. 21, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Genetic Signatures and its competitors. According to the industry distribution chart, Genetic Signatures ranks #199 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 93.4%.
Is Genetic Signatures' FCF Yield % too high?
Genetic Signatures' current FCF Yield % is -71.17. Based on the distribution chart, Genetic Signatures ranks #199 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Genetic Signatures' FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #199 out of 213 companies for FCF Yield %. This places Genetic Signatures in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Genetic Signatures and its competitors. Genetic Signatures's current FCF Yield % is -71.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current FCF Yield % is -71.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current FCF Yield % is -71.17 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
